Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acelrx Pharmaceutica (ACRX)

Acelrx Pharmaceutica (ACRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,564
  • Shares Outstanding, K 119,180
  • Annual Sales, $ 5,420 K
  • Annual Income, $ -40,380 K
  • 60-Month Beta 0.82
  • Price/Sales 22.45
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ACRX with:

Options Overview

Details
  • Implied Volatility 456.19%
  • Historical Volatility 38.46%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 456.19% on 09/16/21
  • IV Low 109.18% on 06/07/21
  • Put/Call Vol Ratio 0.02
  • Today's Volume 47
  • Volume Avg (30-Day) 342
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 12,173
  • Open Int (30-Day) 17,598

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9701 +5.14%
on 08/18/21
1.1900 -14.29%
on 08/26/21
+0.0856 (+9.16%)
since 08/17/21
3-Month
0.7500 +36.00%
on 08/17/21
1.5500 -34.19%
on 07/14/21
-0.3900 (-27.66%)
since 06/17/21
52-Week
0.7500 +36.00%
on 08/17/21
2.9400 -65.31%
on 02/09/21
-0.3500 (-25.55%)
since 09/17/20

Most Recent Stories

More News
AcelRx Pharmaceuticals to Participate in Two September Investor Conferences

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised...

ACRX : 1.0300 (+0.98%)
Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG)

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Lifshitz Law Firm, P.C.

ACRX : 1.0300 (+0.98%)
FREQ : 7.16 (+0.85%)
RLX : 4.87 (-2.01%)
WPG : 1.0600 (+3.92%)
Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically...

ACRX : 1.0300 (+0.98%)
Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically...

ACRX : 1.0300 (+0.98%)
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ACRX : 1.0300 (+0.98%)
AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results

/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically...

ACRX : 1.0300 (+0.98%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of its officers.   The class...

ACRX : 1.0300 (+0.98%)
ACRX Last Few Hours to Deadline: Shareholders With Losses Exceeding $50K in AcelRx Pharmaceuticals, Inc. Are Encouraged to Contact Bronstein, Gewirtz & Grossman, LLC

NEW YORK, NY / ACCESSWIRE / August 9, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ('AcelRx' or 'the Company')...

ACRX : 1.0300 (+0.98%)
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 9, 2021) - , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. ("AcelRx"...

ACRX : 1.0300 (+0.98%)
ACRX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021

New York, New York--(Newsfile Corp. - August 9, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or...

ACRX : 1.0300 (+0.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and...

See More

Key Turning Points

3rd Resistance Point 1.0600
2nd Resistance Point 1.0400
1st Resistance Point 1.0300
Last Price 1.0300
1st Support Level 1.0000
2nd Support Level 0.9800
3rd Support Level 0.9700

See More

52-Week High 2.9400
Fibonacci 61.8% 2.1034
Fibonacci 50% 1.8450
Fibonacci 38.2% 1.5866
Last Price 1.0300
52-Week Low 0.7500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar